CN87102761A - 取代硫代环链烯并(3,2-b)吡啶和其组合物的制备方法及使用方法 - Google Patents
取代硫代环链烯并(3,2-b)吡啶和其组合物的制备方法及使用方法 Download PDFInfo
- Publication number
- CN87102761A CN87102761A CN87102761.5A CN87102761A CN87102761A CN 87102761 A CN87102761 A CN 87102761A CN 87102761 A CN87102761 A CN 87102761A CN 87102761 A CN87102761 A CN 87102761A
- Authority
- CN
- China
- Prior art keywords
- compound
- pyridine
- carboxylic acid
- hydrogen
- ethyl ester
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 title claims description 34
- 239000000203 mixture Substances 0.000 title claims description 14
- 150000003222 pyridines Chemical class 0.000 title abstract 2
- 150000001875 compounds Chemical class 0.000 claims description 87
- RAHZWNYVWXNFOC-UHFFFAOYSA-N sulfur dioxide Inorganic materials O=S=O RAHZWNYVWXNFOC-UHFFFAOYSA-N 0.000 claims description 40
- 239000004291 sulphur dioxide Substances 0.000 claims description 39
- QQVIHTHCMHWDBS-UHFFFAOYSA-N perisophthalic acid Natural products OC(=O)C1=CC=CC(C(O)=O)=C1 QQVIHTHCMHWDBS-UHFFFAOYSA-N 0.000 claims description 36
- 239000004913 cyclooctene Substances 0.000 claims description 23
- QPJORFLSOJAUNL-UHFFFAOYSA-N dibenzo[a,d][7]annulene Chemical compound C1=CC2=CC=CC=C2CC2=CC=CC=C21 QPJORFLSOJAUNL-UHFFFAOYSA-N 0.000 claims description 23
- 125000000217 alkyl group Chemical group 0.000 claims description 17
- -1 mesyloxy, pyridyl Chemical group 0.000 claims description 17
- URYYVOIYTNXXBN-UPHRSURJSA-N cyclooctene Chemical compound C1CCC\C=C/CC1 URYYVOIYTNXXBN-UPHRSURJSA-N 0.000 claims description 14
- 238000006243 chemical reaction Methods 0.000 claims description 13
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 12
- 238000002360 preparation method Methods 0.000 claims description 11
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 10
- 239000002253 acid Substances 0.000 claims description 10
- 239000011575 calcium Substances 0.000 claims description 10
- 229910052791 calcium Inorganic materials 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 125000004494 ethyl ester group Chemical group 0.000 claims description 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 10
- 125000003545 alkoxy group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 229910052799 carbon Inorganic materials 0.000 claims description 8
- 125000000623 heterocyclic group Chemical group 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 150000003839 salts Chemical class 0.000 claims description 7
- 125000004432 carbon atom Chemical group C* 0.000 claims description 6
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 6
- LULAYUGMBFYYEX-UHFFFAOYSA-N 3-chlorobenzoic acid Chemical compound OC(=O)C1=CC=CC(Cl)=C1 LULAYUGMBFYYEX-UHFFFAOYSA-N 0.000 claims description 5
- 239000002585 base Substances 0.000 claims description 5
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 5
- WEYMRIJRWNCSFV-UHFFFAOYSA-N thieno[3,2-b]pyridine-6-carboxylic acid Chemical compound OC(=O)C1=CN=C2C=CSC2=C1 WEYMRIJRWNCSFV-UHFFFAOYSA-N 0.000 claims description 5
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims description 4
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
- 125000004414 alkyl thio group Chemical group 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 4
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 4
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 4
- 125000000590 4-methylphenyl group Chemical group [H]C1=C([H])C(=C([H])C([H])=C1*)C([H])([H])[H] 0.000 claims description 3
- 239000003810 Jones reagent Substances 0.000 claims description 3
- 239000003513 alkali Substances 0.000 claims description 3
- 125000001118 alkylidene group Chemical group 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 3
- 125000004105 2-pyridyl group Chemical group N1=C([*])C([H])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000000175 2-thienyl group Chemical group S1C([*])=C([H])C([H])=C1[H] 0.000 claims description 2
- 125000001541 3-thienyl group Chemical group S1C([H])=C([*])C([H])=C1[H] 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 2
- 125000004786 difluoromethoxy group Chemical group [H]C(F)(F)O* 0.000 claims description 2
- 125000001188 haloalkyl group Chemical group 0.000 claims description 2
- WCPAKWJPBJAGKN-UHFFFAOYSA-N oxadiazole Chemical compound C1=CON=N1 WCPAKWJPBJAGKN-UHFFFAOYSA-N 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims 4
- 150000002431 hydrogen Chemical class 0.000 claims 3
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims 2
- 150000001721 carbon Chemical group 0.000 claims 2
- 230000003647 oxidation Effects 0.000 claims 2
- 238000007254 oxidation reaction Methods 0.000 claims 2
- NLLHXVBITYTYHA-UHFFFAOYSA-N Nitrofor Chemical compound CCN(CC)C1=C([N+]([O-])=O)C=C(C(F)(F)F)C=C1[N+]([O-])=O NLLHXVBITYTYHA-UHFFFAOYSA-N 0.000 claims 1
- 239000000654 additive Substances 0.000 claims 1
- 230000000996 additive effect Effects 0.000 claims 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 1
- 229940125782 compound 2 Drugs 0.000 claims 1
- 230000018044 dehydration Effects 0.000 claims 1
- 238000006297 dehydration reaction Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 229910052760 oxygen Inorganic materials 0.000 claims 1
- 239000001301 oxygen Substances 0.000 claims 1
- 208000009079 Bronchial Spasm Diseases 0.000 abstract description 2
- 208000014181 Bronchial disease Diseases 0.000 abstract description 2
- 206010006482 Bronchospasm Diseases 0.000 abstract description 2
- 229940127291 Calcium channel antagonist Drugs 0.000 abstract description 2
- 208000024172 Cardiovascular disease Diseases 0.000 abstract description 2
- 230000001088 anti-asthma Effects 0.000 abstract 1
- 239000000924 antiasthmatic agent Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 33
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 22
- 239000000243 solution Substances 0.000 description 16
- 239000000047 product Substances 0.000 description 15
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 14
- 239000007787 solid Substances 0.000 description 12
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 9
- 238000001914 filtration Methods 0.000 description 8
- 230000005764 inhibitory process Effects 0.000 description 8
- 229960005425 nitrendipine Drugs 0.000 description 8
- 210000001519 tissue Anatomy 0.000 description 8
- 239000002904 solvent Substances 0.000 description 7
- 238000005406 washing Methods 0.000 description 7
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 6
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 238000000926 separation method Methods 0.000 description 6
- PVHUJELLJLJGLN-INIZCTEOSA-N (S)-nitrendipine Chemical compound CCOC(=O)C1=C(C)NC(C)=C(C(=O)OC)[C@@H]1C1=CC=CC([N+]([O-])=O)=C1 PVHUJELLJLJGLN-INIZCTEOSA-N 0.000 description 5
- JDCBWJCUHSVVMN-UHFFFAOYSA-N but-3-en-2-amine Chemical compound CC(N)C=C JDCBWJCUHSVVMN-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 238000001291 vacuum drying Methods 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- NHQDETIJWKXCTC-UHFFFAOYSA-N 3-chloroperbenzoic acid Chemical compound OOC(=O)C1=CC=CC(Cl)=C1 NHQDETIJWKXCTC-UHFFFAOYSA-N 0.000 description 4
- ZETIVVHRRQLWFW-UHFFFAOYSA-N 3-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC(C=O)=C1 ZETIVVHRRQLWFW-UHFFFAOYSA-N 0.000 description 4
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 4
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 4
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 4
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 4
- 150000001336 alkenes Chemical class 0.000 description 4
- 239000013078 crystal Substances 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 239000011259 mixed solution Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 239000000741 silica gel Substances 0.000 description 4
- 229910002027 silica gel Inorganic materials 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- YNGDWRXWKFWCJY-UHFFFAOYSA-N 1,4-Dihydropyridine Chemical compound C1C=CNC=C1 YNGDWRXWKFWCJY-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 150000001299 aldehydes Chemical class 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000706 filtrate Substances 0.000 description 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 230000016160 smooth muscle contraction Effects 0.000 description 3
- 125000000446 sulfanediyl group Chemical group *S* 0.000 description 3
- UWYZHKAOTLEWKK-UHFFFAOYSA-N 1,2,3,4-tetrahydroisoquinoline Chemical compound C1=CC=C2CNCCC2=C1 UWYZHKAOTLEWKK-UHFFFAOYSA-N 0.000 description 2
- LBUJPTNKIBCYBY-UHFFFAOYSA-N 1,2,3,4-tetrahydroquinoline Chemical compound C1=CC=C2CCCNC2=C1 LBUJPTNKIBCYBY-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 206010003497 Asphyxia Diseases 0.000 description 2
- CTMCCBPMSKPARO-UHFFFAOYSA-N CC(N)=CC(=O)OCCO Chemical compound CC(N)=CC(=O)OCCO CTMCCBPMSKPARO-UHFFFAOYSA-N 0.000 description 2
- FKLJPTJMIBLJAV-UHFFFAOYSA-N Compound IV Chemical compound O1N=C(C)C=C1CCCCCCCOC1=CC=C(C=2OCCN=2)C=C1 FKLJPTJMIBLJAV-UHFFFAOYSA-N 0.000 description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 206010019280 Heart failures Diseases 0.000 description 2
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 208000019695 Migraine disease Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
- 208000006399 Premature Obstetric Labor Diseases 0.000 description 2
- 206010036600 Premature labour Diseases 0.000 description 2
- LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- MUCRYNWJQNHDJH-OADIDDRXSA-N Ursonic acid Chemical compound C1CC(=O)C(C)(C)[C@@H]2CC[C@@]3(C)[C@]4(C)CC[C@@]5(C(O)=O)CC[C@@H](C)[C@H](C)[C@H]5C4=CC[C@@H]3[C@]21C MUCRYNWJQNHDJH-OADIDDRXSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000004523 agglutinating effect Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000000845 cartilage Anatomy 0.000 description 2
- 229940117975 chromium trioxide Drugs 0.000 description 2
- WGLPBDUCMAPZCE-UHFFFAOYSA-N chromium trioxide Inorganic materials O=[Cr](=O)=O WGLPBDUCMAPZCE-UHFFFAOYSA-N 0.000 description 2
- GAMDZJFZMJECOS-UHFFFAOYSA-N chromium(6+);oxygen(2-) Chemical compound [O-2].[O-2].[O-2].[Cr+6] GAMDZJFZMJECOS-UHFFFAOYSA-N 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- NLFBCYMMUAKCPC-KQQUZDAGSA-N ethyl (e)-3-[3-amino-2-cyano-1-[(e)-3-ethoxy-3-oxoprop-1-enyl]sulfanyl-3-oxoprop-1-enyl]sulfanylprop-2-enoate Chemical compound CCOC(=O)\C=C\SC(=C(C#N)C(N)=O)S\C=C\C(=O)OCC NLFBCYMMUAKCPC-KQQUZDAGSA-N 0.000 description 2
- XYIBRDXRRQCHLP-UHFFFAOYSA-N ethyl acetoacetate Chemical compound CCOC(=O)CC(C)=O XYIBRDXRRQCHLP-UHFFFAOYSA-N 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- 206010027599 migraine Diseases 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 208000010125 myocardial infarction Diseases 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 238000006213 oxygenation reaction Methods 0.000 description 2
- 239000008194 pharmaceutical composition Substances 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 208000026440 premature labor Diseases 0.000 description 2
- 238000010992 reflux Methods 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- 239000012279 sodium borohydride Substances 0.000 description 2
- 229910000033 sodium borohydride Inorganic materials 0.000 description 2
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 238000007738 vacuum evaporation Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- FMCAFXHLMUOIGG-IWFBPKFRSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2r)-2-formamido-3-sulfanylpropanoyl]amino]-3-methylbutanoyl]amino]-3-(4-hydroxy-2,5-dimethylphenyl)propanoyl]amino]-4-methylsulfanylbutanoic acid Chemical compound O=CN[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@H](C(=O)N[C@@H](CCSC)C(O)=O)CC1=CC(C)=C(O)C=C1C FMCAFXHLMUOIGG-IWFBPKFRSA-N 0.000 description 1
- NQBWNECTZUOWID-UHFFFAOYSA-N (E)-cinnamyl (E)-cinnamate Natural products C=1C=CC=CC=1C=CC(=O)OCC=CC1=CC=CC=C1 NQBWNECTZUOWID-UHFFFAOYSA-N 0.000 description 1
- CMWKITSNTDAEDT-UHFFFAOYSA-N 2-nitrobenzaldehyde Chemical compound [O-][N+](=O)C1=CC=CC=C1C=O CMWKITSNTDAEDT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 206010020601 Hyperchlorhydria Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 1
- 206010022562 Intermittent claudication Diseases 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 239000012839 Krebs-Henseleit buffer Substances 0.000 description 1
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000028484 Urethral disease Diseases 0.000 description 1
- WDJHALXBUFZDSR-UHFFFAOYSA-N acetoacetic acid Chemical compound CC(=O)CC(O)=O WDJHALXBUFZDSR-UHFFFAOYSA-N 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 208000026935 allergic disease Diseases 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002220 antihypertensive agent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- CUBCNYWQJHBXIY-UHFFFAOYSA-N benzoic acid;2-hydroxybenzoic acid Chemical compound OC(=O)C1=CC=CC=C1.OC(=O)C1=CC=CC=C1O CUBCNYWQJHBXIY-UHFFFAOYSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 230000005587 bubbling Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000007810 chemical reaction solvent Substances 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- NQBWNECTZUOWID-QSYVVUFSSA-N cinnamyl cinnamate Chemical compound C=1C=CC=CC=1\C=C/C(=O)OC\C=C\C1=CC=CC=C1 NQBWNECTZUOWID-QSYVVUFSSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 239000012230 colorless oil Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 125000004925 dihydropyridyl group Chemical class N1(CC=CC=C1)* 0.000 description 1
- 238000007865 diluting Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-N ethanesulfonic acid Chemical compound CCS(O)(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-N 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- HCPOCMMGKBZWSJ-UHFFFAOYSA-N ethyl 3-hydrazinyl-3-oxopropanoate Chemical compound CCOC(=O)CC(=O)NN HCPOCMMGKBZWSJ-UHFFFAOYSA-N 0.000 description 1
- OAYLNYINCPYISS-UHFFFAOYSA-N ethyl acetate;hexane Chemical compound CCCCCC.CCOC(C)=O OAYLNYINCPYISS-UHFFFAOYSA-N 0.000 description 1
- UREBWPXBXRYXRJ-UHFFFAOYSA-N ethyl acetate;methanol Chemical compound OC.CCOC(C)=O UREBWPXBXRYXRJ-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 230000002496 gastric effect Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 229910000042 hydrogen bromide Inorganic materials 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 208000021156 intermittent vascular claudication Diseases 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 230000001788 irregular Effects 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N mandelic acid Chemical compound OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000005649 metathesis reaction Methods 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- RIWRFSMVIUAEBX-UHFFFAOYSA-N n-methyl-1-phenylmethanamine Chemical compound CNCC1=CC=CC=C1 RIWRFSMVIUAEBX-UHFFFAOYSA-N 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- KMUONIBRACKNSN-UHFFFAOYSA-N potassium dichromate Chemical group [K+].[K+].[O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O KMUONIBRACKNSN-UHFFFAOYSA-N 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- NPRDHMWYZHSAHR-UHFFFAOYSA-N pyridine;trioxochromium Chemical compound O=[Cr](=O)=O.C1=CC=NC=C1.C1=CC=NC=C1 NPRDHMWYZHSAHR-UHFFFAOYSA-N 0.000 description 1
- 229940107700 pyruvic acid Drugs 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000007430 reference method Methods 0.000 description 1
- 239000012047 saturated solution Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000012258 stirred mixture Substances 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 150000003457 sulfones Chemical class 0.000 description 1
- 235000010269 sulphur dioxide Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 125000005424 tosyloxy group Chemical group S(=O)(=O)(C1=CC=C(C)C=C1)O* 0.000 description 1
- 210000005062 tracheal ring Anatomy 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 125000005034 trifluormethylthio group Chemical group FC(S*)(F)F 0.000 description 1
- 210000001170 unmyelinated nerve fiber Anatomy 0.000 description 1
- 210000001635 urinary tract Anatomy 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Endocrinology (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Catalysts (AREA)
- Manufacturing Of Magnetic Record Carriers (AREA)
Abstract
本发明介绍一类新颖的取代环链烯首[3,2-b]吡啶,这类化合物能用作钙管对抗剂,具有治疗心血管疾病,止喘和抑止支气管痉挛作用。
Description
本发明是关于某种取代的硫代环链烯并〔3,2-b〕吡啶,这类化合物具有心血管、止喘,抑止支气管痉挛、抑制胃分泌、细胞保护和抑制血小板聚集的活性,能有效的用作为钙管对抗剂。此外,它们也能有效地用于治疗胃肠道运动过强和腹泻等方面。本发明还涉及到这些化合物和其组合物的制备方法,使用方法和新颖的中间体。
美国专利4,285,955号和4,483,985号(为上面所提专利的一部分)公开了在单一的二氢吡啶上的无环砜取代,该二氢吡啶具有钙管对抗剂性能。但是该化合物在化学性质上不同于本发明化合物。
在化学会杂志,Perkin Trans.2,1392-7(1074)上,G.P.A.Pagani公开了10-苯基-2H-硫代吡喃并〔3,2-b〕喹啉,然而这些化合物却不是钙管对抗剂。
美国专利4,532,248号公开了二氢吡啶的一个属类,其中包括同二氢吡啶核稠合的环状砜,该属类的全部化合物都有强心活性。而本发明的化合物不同于美国专利4,532,248号申请的化合物,是具有药理活性的强的钙对抗剂。
本发明物-取代硫代环链烯并〔3,2-b〕吡啶或其药物可接受的酸加成盐通式如下:
式中n为1到12的一个整数;R1为氢,氨基,烷基,卤代烷基或CH2OR2;R2为含有1-8个碳原子的直链或支链烷基,含3-7个碳原子的环烷基,或至少2个碳原子以上的亚烷基-X,这里X代表烷氧基、羟基,卤,对一甲苯磺酰氧基,甲磺酰氧基,氨基,吡啶基或-NR4R5,其中R4和R5可相同也可不同,它们选自氢,烷基,环烷基,苯基,苄基,苯乙基,或者R4,R5和氮原子相互连接组成5,6或7元杂环,杂环可任意地含有氧或硫原子或另外的氮原子,或所述的杂环可以同苯环稠合,诸如二氢吲哚,异二氢吲哚,四氢喹啉或四氢异喹啉,在这里所说的杂环是哌嗪并,并且在4位可以被R6取代基所取代,R6是选自烷基,环烷基,苯基,或由烷氧基,卤,烷基,硝基或三氟甲基取代的苯基;R3为2-吡啶基,3-吡啶基,有1或多个卤,硝基,烷氧基,烷硫基,氰基,烷氧羰基,二氟甲氧基,三氟甲硫基或烷基磺酰基在2,4,5或6位取代的3-吡啶基;2-噻吩基,3-噻吩基,2,1,3-苯并噁二唑基,2,1,3-苯并噻二唑基或有1或多个选自氢,烷基,烷氧基,氰基,烷氧羰基,烷硫基,二氟甲氧基,二氟甲硫基,烷基磺酰基,卤,硝基或三氟甲基在2至6位上任意被取代的苯基。
由于吡啶环R3上的基团,使得本发明化合物不对称,因此存在光学对映体,这都构成本发明的一部分。能用本领域的技术人员已知的方法分离对映体,例如分段重结晶出对映性纯酸的非对映盐。因此,可在Pirkle柱里用色谱法分离对映体。
本发明还介绍了一个制备通式Ⅰ化合物的方法,在下面将详细描述本方法。
本发明还包括一些中间体和其制备方法。
本发明较优先的化合物为:
1)2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸乙酯。
2)2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸N,N-二甲氨基乙酯。
3)2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸N-苄基-N-甲氨基乙酯。
4)3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代-吡喃并〔3,2-b〕吡啶-7-羧酸乙酯。
5)3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃〔3,2-b〕吡啶-7-羧酸N,N-二甲氨基乙酯。
6)3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃〔3,2-b〕吡啶-7-羧酸N-苄基-N-甲氨基乙酯。
7)3,4,5,8-四氢-6-甲基-8-(2,3,4,5,6-五氟苯基)-1,1-二氧代-2H-硫代吡喃〔3,2-b〕吡啶-7-羧酸N-苄基-N-甲氨基乙酯。
8)9-(2,3,4,5,6-五氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸乙酯。
9)2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
10)2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N,N-二甲氨基乙酯。
11)2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸2-甲氧基乙酯。
12)9-(2,3,4,5,6-五氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酸。
13)10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸乙酯。
14)10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
15)3,4,5,6,7,10-六氢-8-甲基-10-(3-硝基苯基)-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
16)11-(3-硝基苯基)-2,3,4,5,6,7,8,11-八氢-9-甲基-1,1-二氧硫代环壬烯并〔3,2-b〕吡啶-10-羧酸N-苄基-N-甲氨基乙酯。
17)2,3,4,5,6,9-六氢-6-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
18)9-(2-氯苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
19)9-(2,3-二氯苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
20)9-(2-氯-6-氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
21)9-(2-二氟甲氧基苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
22)2,3,4,5,6,9-六氢-7-甲基-9-(2-三氟甲基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
23)10-(2-氯苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
24)10-(2,3-二氯苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
25)10-(2-二氟甲氧基苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
26)10-(2-氯-6-氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
27)10-(2-氯-3-三氟甲基苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
28)12-(2-氯-3-三氟甲基苯基)-2,3,4,5,6,7,8,11-八氢-9-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-10-羧酸N-苄基-N-甲氨基乙酯。
29)10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-甲基-N-苯氨基乙酯。
本发明化合物是强钙离子抑制剂,其直接进入平滑肌组织内起到松驰或防止钙机理引起的组织收缩。本发明化合物在心血管病症治疗方面也具有治疗作用,其中包括血管紧张,局部缺血,咽峡炎,心律失常,充血的心力衰竭外周血管病症如间歇性跛行,偏头痛,心肌梗塞,血小板聚集和发作。此外,本发明化合物对于例如下列病症也具有疗效:过敏性,食管痉挛,早产和泌尿道,胃酸过多,膜完整病症。通过下面描述,能更容易了解本发明化合物,组合物及实施本发明的多种方法。
这里所用的各种术语应该理解如下:
除另有规定外术语“烷基”表示只含有碳和氢的饱和直链,支链或环取代基,并且含碳原子数是1至8。术语“低级烷氧基”是指上述含碳原子数少于4个的低级烷基链。术语“卤”代表氟、氯、溴和碘。
短语“药物可接受的盐”是指具有期望药理活性的游离硷的盐,其中游离硷是合乎需要的但并非是生物性的。这些盐可从无机或有机酸衍生得到。无机酸例如为盐酸,硝酸,氢溴酸,硫酸或磷酸。有机酸的例子为醋酸,丙酸,乙醇酸,乳酸,丙酮酸,丙二酸,琥珀酸,苹果酸,马来酸,富马酸,酒石酸,柠檬酸,苯甲酸,肉桂酸,扁桃酸,甲磺酸,乙磺酸,对甲基苯磺酸,水杨酸等。
可用常规的药物合成技术配制含有本发明的药物组合物,本发明化合物是作为活性组分同药物载体直接混合。根据如气雾的,静脉的,舌下的,口服的或局部的给药而所需的制备形式,可以采用各种类型的载体。在制备口服剂量形式的组合物中,如是以口服液形式制备如悬浮液,剂和溶液形式时,可使用任何常规的药物介质,例如水,脂肪族二元醇类,油类,醇类,增香剂,防腐剂,着色剂等;而如是以口服固体形式制备如粉末,胶囊和片剂时,载体可以例如是淀粉,糖,稀释剂,粒剂,润滑剂,结合剂,崩解剂等。因为片剂和胶囊给药方便,所以它们是主要的便利口服剂单位形式,显然在这里是使用固体药物载体。如果需要的话,可用标准技术制成包有糖衣或肠溶衣的片剂。如肠胃外给药,载体通常包含无菌水,用其来助溶或起到防腐作用,虽然这里也可包括一些其它组分。同样也可制备注射悬浮液,此时可使用合适的液体或溶液。在药物组合物例如片剂,胶囊,粉末,注射剂,一茶匙等中,每剂量单位含有约0.001至约100毫克/公斤的活性组分,较好是约0.001至约20毫克/公斤。
可按如下反应步骤合成本发明的新颖化合物,式中R1,R2,R3,R4,R5如前定义,MCPBA代表间氯过苯甲酸,Y为对甲苯基或烷基。
砜合成
二氧硫代环链烯并〔3,2-b〕吡啶的合成步骤:
参照上面所反应步骤,如下进行本发明化合物的合成:
按照化学通极110卷,1069-1085页(1977)B.Listert,P.Kuffner,和T.J.Arackel所公开的方法合成通式Ⅴ的3-酮环砜(例如其中n为1至4)。
但是遇到n为2即3-氧代-四氢硫代苯-1,1-二氧化物情况时,上述参考方法就变得非常繁琐。然而发现用本发明方法,却可以从相应的3-环硫化合物简单并高产的制得通式Ⅴ化合物(其中n是2或3)。通式Ⅱ的化合物可以按美国化学会杂志74卷1569-74页(1952年)E.A.Fehnel公开的方法加以制备。
在还原剂存在下,将化合物Ⅱ的3-酮部分还原为醇(化合物Ⅲ),较好的还原剂是硼氢化钠,其它的还原剂例如乙硼烷、氢化锂铝或氰硼氢化钠也可以使用。然后最好用间氯过苯甲酸把化合物Ⅲ氧化为化合物Ⅳ,其它合适的氧化剂为过氧化氢或高碘酸钠。最后,最好使用琼斯试剂(三氧化铬的稀硫酸溶液,它是加入在醇的丙酮溶液里的),把化合物Ⅳ羟基部分再氧化成相应的化合物Ⅴ的酮部分,其它合适的氧化剂为重铬酸钾或科林试剂(三氧化铬的吡啶溶液)。
可按照Listert及其等人的参考文献和前面提到的方法制备3-酮7,8和9元环状砜。
通式Ⅰ化合物,其中n为1至12(在下列反应步骤中指定其为化合物Ⅰa)可以如下制备,在室温下于乙醇中搅拌等摩尔量的3-氧代四氢硫代苯-1,1-二氧化物,通式Ⅲ的适当取代的醛和通式Ⅵ的取代的3-氨基酯24小时(见实例4),所得通式为Ⅷ的羟基中间体为一个新化合物。然后在甲苯回流温度下,脱水加热化合物Ⅷ24小时,得到化合物Ⅰa(见实例5)。
按照实例6的方法,回流搅拌等摩尔量的通式Ⅴ酮式砜,通式Ⅶ的醛和通式Ⅵ的取代3-氨基酯的乙醇混合溶液约16小时,直接得到通式为Ⅰ(其中n为3至12)的6到15元环状砜产品。所得的产品(其中n为3至12)定为化合物Ⅰb和/或Ⅻ,可以注意到化合物Ⅰb实际上同化合物Ⅰa是一样的,只不过是合成的路线不一样而已。所形成的新化合物Ⅻ能够与乙醇盐酸或甲苯在加热下转化成Ⅰb。
R2为亚烷基的化合物Ⅰ也能制备获得,可用通式Ⅴ的化合物和通式为Ⅶ的相应醛以及通式Ⅵa的2-羟基乙基-3-氨基丁烯酸酯进行反应,制备得到通式Ⅰc的中间体(见实例Ⅷ),然后通式为Ⅰc的中间体最好与通式Ⅸ的化合物(其中Y为对甲苯基或烷基)一起回流反应,被转化成磺酰基酯,用通式Ⅺ的相应氨对式Ⅹ的磺酰基酯进行置换反应得到通式Ⅰd的化合物(见实例9)。
在下面实例6和10中列举了由化合物Ⅴ,Ⅶ和Ⅵ反应直接制备n为3至12的化合物Ⅰb。
上面讨论的各种反应步骤引用了下列的附加参考文献。
化学会志,Perkin Trans第2卷P1392-7(1974年),G.A.Pagani的文章。
化学会志(C)P2171-76(1967年),K.G.Mason,M.A.Smith和E.S.Stern的极道。
Maruko Seiyaku的日本专利申请第58201764号(1984年)。
下面将给出本发明具体的实例,但不能把它们认作为是对本发明的限制。
实例1
四氢硫代吡喃-3-醇
在四氢硫代吡喃-3-酮(参考4)(10.0克,0.086摩尔)的乙醇溶液里,于5分钟加入硼氢化钠(3.25克,0.086摩尔)。经搅拌30分钟后,加入1N盐酸溶液至pH5,水稀释反应混合液并用二氯甲烷(6×50毫升)萃取。有机相经硫酸镁干燥,过滤和真空浓缩后,蒸馏(约100乇,158℃)得到6.8克产品。
H′核磁共振CDCl33.9(宽单峰,1H)2.2-2.9(多重峰,5H)1.4-2.2(多重峰,4H)。
实例2
四氢硫代吡喃-3-醇-1,1-二氧化物
把四氢硫代吡喃-3-醇(6.8克,0.58摩尔)和氯仿(250毫升)的溶液冷至0℃,并维持温度在10℃以下的速率加入间氯过苯甲酸(23.4克,0.135摩尔)来进行处理。加毕后,在0℃下搅拌粘稠状混合物1小时,然后室温下搅拌30分钟。过滤去除固体后真空蒸发滤液。用酒精稀释所得固体并真空蒸发除去余留的氯仿。固体再用水(150毫升)稀释并过滤。真空蒸发滤液,剩余的水用甲苯共沸加以除去,这样得到7.5克的无色油状产品。
H′核磁共振D-DMSO4.3(宽单峰,1H)3.4-4.0(多重峰,1H)2.7-3.3(多重峰,4H)1.2-2.1(多重峰,4H)。
实例3
四氢硫代吡喃-3-酮-1,1-二氧化物
在四氢硫代吡喃-3-醇-1,1-二氧化物(7.5克,0.05摩尔)的丙酮(150毫升)溶液中缓慢地加入足够量的琼斯试剂,使得在无需再加入试剂情况下维持溶液为棕色至少10分钟,通过加入异丙醇(5毫升)除去过量的试剂。混合液经过无水硫酸镁得到过滤,铬盐用丙酮洗涤三次。真空除去溶剂得到一固体(经由乙醇研制)。过滤分离所得晶体并用二乙醚漂洗,干燥得到5.0克产品,
H′核磁共振CPCL34.0(单峰,2H)3.3(三重峰,2H)2.6(三重峰,2H)2.3(多重峰,2H)。
实例4
2,3,3a,4,7,7a-六氢-3a-羟基-5-甲基-7-(2-硝基苯基)-1,1-二氧代-噻吩并〔3,2-b〕吡啶-6-羧酸甲酯
四氢硫代苯-3-氧代-1,1-二氧化物(1,3克,0.01摩尔),2-硝基苯甲醛(1.5克,0.01摩尔)和3-氨基丁烯酸甲酸的乙醇(20毫升)溶液搅拌过夜,所得晶体过滤分离并分别用乙醇和乙醚二次洗涤,然后高真空干燥24小时得2,54克产品,熔点为175-179℃(分解)。
实例5
2,3,4,7-四氢-5-甲基-7-(2-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸甲酸
2,3,3a,4,7,7a-六氢-3a-羟基-5-甲基-7-(2-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸甲酯(2.5克,0.0065摩尔)和甲苯(60毫升)的混合液回流24小时。真空除去溶剂;用乙醇结晶得到固体,晶体二次乙醚液涤并高真空干燥48小时,得到熔点215-217℃的产品1.78克。
实例6
3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸甲酯。
四氢硫代吡喃-3-酮-1,1-二氧化物(0.830克,0.0056摩尔),3-硝基苯甲醛(0.846克,0.0056摩尔)和3-氨基丁烯酸甲酯(0.644克,0.0056摩尔)的醇(20毫升)混合液回流16小时,冷却后,过滤分离所得固体并用乙醚洗涤,然后在40℃下真空干燥4小时,得到熔点为236-238℃的产品0.620克。
实例7
3-氨基丁烯酸2-羟乙酯
用无水氨气鼓泡3-氧代-丁酸2-羟基乙酯(25克,0.17摩尔)(参照5)的乙醇(250毫升)溶液20分钟,然后室温搅拌该溶液16小时。真空除去溶剂,所得油状物进行硅胶(350克)色谱层析,使用乙酸乙酯-己烷(60∶40)为洗脱液。合并浓缩部分并真空除去溶剂得到产品;
H′核磁共振CDCL34.33(t,2H)3.85(t,2H)3.55(S.1H)2.85(宽单峰,1H)2,31(S,3H)
实例8
3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸2-羟乙酯
四氢硫代吡喃并-3-酮-1,1-二氧化物(2.80克,0.0189摩尔),3-硝基苯甲醛(2.85克,0.0189摩尔),2-羟乙基-3-氨基丁烯酸酯(3,28克,0.0226摩尔),乙酸铵(0.291克,0.0038摩尔)和乙醇(35毫升)的混合液回流16小时,冷却至室温后,过滤分离出所产生的固体,然后用乙醇和乙醚洗涤。在室温减压干燥产品16小时,得熔点为233-235℃的产品。
实例9
2,3,4,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-5H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸N-苄基-N-甲基-2-氨基乙酯,半草酸盐
3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸2-羟乙酯(2.5克1,0.0061摩尔),对苯磺酰氯(4.65克,0.0244摩尔),三乙胺(2.46克,0.0244摩尔)和二氯甲烷(25毫升)的混合溶液回流4.5小时,接着冷却反应混合液并真空除去溶剂。所得油状物用硅胶(170克)进行色谱层析,使用乙酸乙酯-甲醇(95∶5)为洗脱剂。合并含甲苯磺酸盐〔H′核磁共振CPCL37.3-8.2(多重峰,8H)6.9(单峰,1H)5.2(单峰,1H)〕的浓缩液部分,在该溶液中加入N-苄基-N-甲基胺(4.69克,0.0387摩尔)。真空除去溶剂,剩余物室温静置72小时,用硅胶(170克)混合物色谱层析,使用乙酸乙酯和甲醇的混合液(97∶3)为洗脱液。所得分离物溶于乙醚并用草酸的乙醚饱和溶液处理。过滤收集固体,乙醚洗涤并于60℃真空干燥16小时得熔点220-222℃的产品(2.07克)。
实例10
2,3,4,5,6,9六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸乙酯
硫代环庚烯-3-酮-1,1-二氧化物(1,3克,0.008摩尔),3-硝基苯甲醛(1.2克,0.0080摩尔),3-氨基丁烯酸乙酯(1.04克,0.008摩尔)的乙醇(20毫升)溶液回流16小时,真空除去溶剂后,剩余物用硅胶(170克)进行色谱层析,使用乙酸乙酯和己烷(4∶1)为洗脱液。合并浓缩液部分并真空除去溶剂,固体用乙醚研制后,过滤和真空干燥过夜得1.52克熔点为211-213℃的产品。
实例11
3,4,5,7,10,10a-六氢-8-甲基-10-(3-硝基苯基)-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸乙酯
硫代环辛烯-3-酮-1,1-二氧化物(0.35克,0.002摩尔);3-硝基苯甲醛(0.30克,0.002摩尔),3-氨基丁烯酸乙酯(0.20克,0.002摩尔)的乙醇(30毫升)溶液回流16小时,冷至室温后,过滤分离出沉淀黄色物,用乙醚洗涤并真空干燥,得到熔点为211-214℃的产品(0.56克)。
实例12
3,4,5,6,7,10-六氢-8-甲基-10-(3-硝基苯基)-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸乙酯
3,4,5,7,10,10a-六氢-8-甲基-10-(3-硝基苯基)-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸乙酯(0.45克,0.0011摩尔)和甲苯(30毫升)的混合液回流24小时,过滤分离所得固体,并且乙醚洗涤和真空干燥,得到熔点为234-235℃的产品。
经评价本发明化合物的生物性质,显示这些化合物影响钙媒介结果的能力,这包括抑制气管和血管组织平滑肌的收缩。所用评价化合物的筛选制度模型如下:
1,对nitrendipine粘结钙管的抑制。
2,调节组织活性的能力,该组织是依赖于用于气管和血管组织的钙。
3,在哺乳动物中它们被用作为抗高血压剂和/或支气管扩张剂。
基于上面结果,可以相信这些化合物可用于高血压,心肌,局部缺血,咽峡炎,心力衰竭充血,偏头痛,心肌梗死,血小板聚集,发作,过敏,变态反应,气喘,胃分泌痛经,食管痉挛,早产和尿道病症。
表Ⅰ用抑制百分比列出本发明的一些代表性化合物对nitrendipine粘结的抑制以及对依赖于钙的平滑肌收缩的抑制。
抑制nitrendipine粘合的测定按如下步骤进行:
用颈脱位剖开新西兰白色雌性免(1-2公斤),马上取出心脏并加以清洗,然后切成小块,把该组织体5x体积的0.05摩尔Hepes缓冲剂(pH7.4)中均化,所得均体在400Xg情况下离心10分钟;上层清液在42,000Xg的情况下再离心90分钟。所得血小板膜混悬(0.7毫升/克重量)于pH7.4的0.05摩尔Hepes中,并存放在-70℃下至使用。每个测定的粘合管都含有3H-nitrendipine(0.05-0.50毫微摩尔),缓冲剂,膜(0.10毫升)和试验化合物,管中所含总体积量为1.0毫升。在4℃90分钟后,经由Whatman GF/C纤维从未粘结中分离出粘结的nitrendipine。经漂洗后,干燥滤液并在液体闪烁计算器里计数。
从总粘合物中萃取样3H-nitrendipine的非特殊粘合物(在有过量未标记的nitrendipine存在下所计粘合物),得到特殊可放射的粘合nitrendipine,对有试验化合物存在下的特殊粘合nitrendirine的量和没有化合物存在下的粘合物量进行比较,可获得百分比置换(或抑制)。
依照下列方法决定试验抑制依赖钙的平滑肌收缩:
从由注射过量KCL致死的狗中取出气管,把其于4℃下放置在充氧的Krebs-Henseleit缓冲剂中过夜。从支气管未端切下气管环一一个软骨节宽(5-10毫米)。切下软骨后,气管肌肉组织混悬于盛放在25毫升组织浴中的充氧Krebs-Henseleit里(37℃),经60分钟饱和期后,组织体中加入10微摩尔碳酰胆硷,5分钟后清洗组组体并放置50分钟,接着加入50毫摩尔KCL,30分钟后测后组织体收缩,然后清洗组织体并再饱和50分钟,这样于10分钟里加入试验化合物和再加入50毫摩尔kcl。经30分钟后,记录其收缩并测定出控制的百分比抑制。
由药物处理前和后的相应数据计算出平滑肌收缩的抑制百分数。
抑制%=100-100 ((药物处理后的峰响应))/(药物处理前的峰响应)
化合物所具有的比率取决于其所有的抑制百分数。
Claims (17)
1、一种制备具通式Ⅰ化合物或其药物可接受的酸和硷加成盐的方法。
式中n是1-12的一个整数,R1是氢,氨基,烷基,卤代烷基或CH2OR2,R2是含有1-8个碳原子的直链或友链烷基,含3-7个碳原子的环烷基,或至少有2个碳原子以上的亚烷基-X,这里X是是烷氧基,氢,卤,对甲苯磺酰氧基,甲磺酰氧基,吡啶基,氨基或-NR4R5,式中R4和R5可同可不同,它们选自氢,烷基,环烷基,苯基,苄基,苯乙基,或者R4,R5和氮原子相互连接组成5,6或7元杂环,谈杂环可任意含有氧或硫原子或另外的氮原子,或所说的杂环可同苯环稠合,而且这里所说的杂环是吡嗪并,谈吡嗪并在4位上可任意地被R6取代,R6是选自烷基,环烷基,苄基,苯基或由烷氧基,卤,烷基,硝基或三氟甲基取代的苯基,R3是2-吡啶基,3-吡啶基,在吡啶环2,4,5或6位上被一或多个卤,硝基,烷氧基,烷硫基,氰基,烷氧羰基,二氟甲氧基,二氟甲硫基或烷基磺酰基取代的3-吡啶基,2-噻吩基,3-噻吩基,2,1,3-苯并噁二唑基,2,1,3-苯并噻二唑基或有一或有多个选自氢,烷基,烷氧基,氰基,烷氧碳基,烷硫基,二氟甲氧基,二氟甲硫基,烷基磺酰基,卤,硝基或三氟甲基在2至6位上任意取代的苯基;
本发明方法包括通式(Ⅴ)化合物同通式(Ⅵ)化合物和通式R3CHO(Ⅶ)化合物反应制约通式(Ⅷ)的化合物,式中n是2,
接着所说化合物(Ⅷ)经脱水制得通式(Ⅰa)化合物或通式(Ⅰb)化合物,式中n是3,4,5或6,
或者制得(Ⅺ)化合物
式中n是3-12的一个整数,上说后者的方法包括通式(Ⅴ)化合物同通式(Ⅵ)化合物和通式(Ⅶ)化合物的反应,制得通式(Ⅻ)化合物,如需要的话,接着将化合物(Ⅻ)转化成Ⅰb,或者在最终制得通式(Ⅰd)化合物中,将通式(Ⅴ)化合物同通式(Ⅳ)化合物和通式R3CHO(Ⅶ)
然后将所说化合物(Ⅰc)和式YSO2Cl(Y是对甲苯基或烷基)的化合物反应制得通式(Ⅹ)化合物
接着所说化合物(Ⅹ)和式HNR4R5(Ⅺ)化合物反应得到通式(Ⅰd)化合物
3、根据权利要求1的方法,其中所制备的通式Ⅰ化合物是选自下列组成的化合物:2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸乙酯,2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸N,N-二甲氨基乙酯2,3,4,7-四氢-5-甲基-7-(3-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸N-苄基-N-甲氨基乙酯,3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸乙酯和3,4,5,8-四氧-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸N,N-二甲氨基乙酯。
4、根据权利要求1的方法,其中所制备的通式Ⅰ化合物是选自下列组成的化合物,3,4,5,8-四氢-6-甲基-8-(3-硝基苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕-吡啶-7-羧酸N-苄基-N-甲氨基乙酯,3,4,5,8-四氢-6-甲基-8-(2,3,4,5,6-五氟苯基)-1,1-二氧代-2H-硫代吡喃并〔3,2-b〕吡啶-7-羧酸N-苄基-N-甲氨基乙酯,9-(2,3,4,5,6-五氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸乙酯,2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯和2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N,N-二甲氨基乙酯。
5、根据权利要求1的方法,其中所制备的通式Ⅰ化合物是选自下列组成的化合物:2,3,4,5,6,9-六氢-7-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸2-甲氧基乙酯,9-(2,3,4,5,6-五氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯,10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸乙酯,10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯和3,4,5,6,7,10-六氢-8-甲基-10-(3-硝基苯基)-1,1-二氧代-2H-硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
6、根据权利要求1的方法,其中所制备的通式Ⅰ化合物是选自下列组成的化合物:10-(2-二氟甲氧基苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯,10-(2-氯-6-氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯,10-(2-氯-三氟甲基苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯,12-(2-氯-3-三氟甲基苯基)-2,3,4,5,6,7,8,11-八氢-9-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-10-羧酸N-苄基-N-甲氨基乙酯和10-(2,3,4,5,6-五氟苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并并〔3,2-b〕吡啶-9-羧酸N-甲基-N-苯氨基乙酯。
7、根据权利要求1的方法,其中所制备的化合物是2,3,4,5,6,9-六氢-6-甲基-9-(3-硝基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
8、根据权利要求1的方法,其中所制备的化合物是9-(2-氯苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
9、根据权利要求1的方法,其中所制备的化合物是9-(2,3-二氯苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
10、根据权利要求1的方法,其中所制备的化合物是9-(2-氯-6-氟苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
11、根据权利要求1的方法,其中所制备的化合物是9-(2-二氟甲氧基苯基)-2,3,4,5,6,9-六氢-7-甲基-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
12、根据权利要求1的方法,其中所制备的化合物是2,3,4,5,6,9-六氢-7-甲基-9-(2-三氟甲基苯基)-1,1-二氧硫代环庚烯并〔3,2-b〕吡啶-8-羧酸N-苄基-N-甲氨基乙酯。
13、根据权利要求1的方法,其中所制备的化合物是10-(2-氯苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
14、根据权利要求1的方法,其中所制备的化合物是10-(2,3-二氯苯基)-3,4,5,6,7,10-六氢-8-甲基-1,1-二氧硫代环辛烯并〔3,2-b〕吡啶-9-羧酸N-苄基-N-甲氨基乙酯。
15、根据权利要求1的方法,其中所制备的通式(Ⅶ)化合物是2,3,3a,4,7,7a-六氢-3a-羟基-5-甲基-7-(2-硝基苯基)-1,1-二氧代噻吩并〔3,2-b〕吡啶-6-羧酸甲酯。
16、一种制备有效用作为钙管对抗剂的药物理组合物的方法,可制成以整体,局部,口服,舌下,烟雾和静脉内的用量形式,其中包含约0.001毫克/公斤到约100毫克/公斤的权利要求1化合物同药物上可接受的载体混合。
17、根据权利要求22的制备方法,其中所制备的组合物包含约0.001毫克1/公斤到约20毫克/公斤的权利要求1化合物同药物可接受的载体混合。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US849,647 | 1986-04-09 | ||
US06/849,647 US4705785A (en) | 1986-04-09 | 1986-04-09 | Substituted thiacycloalkeno (3,2-b) pyridines and pharmaceutical compositions and method of use |
US07/010,858 US4777167A (en) | 1986-04-09 | 1987-02-04 | Pharmaceutically useful substituted thiacycloalkeno [3,2-b]pyridines, compositions and method of use |
US010,858 | 1987-02-17 | ||
US849647 | 1987-02-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94105615A Division CN1067076C (zh) | 1986-04-09 | 1994-05-18 | 含取代的硫杂环烯并[3,2-b]吡啶的药物组合物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN87102761A true CN87102761A (zh) | 1987-11-04 |
CN1028759C CN1028759C (zh) | 1995-06-07 |
Family
ID=26681670
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN87102761A Expired - Lifetime CN1028759C (zh) | 1986-04-09 | 1987-04-09 | 取代硫杂环烯并(3,2-b)吡啶的制备方法 |
CN94105615A Expired - Lifetime CN1067076C (zh) | 1986-04-09 | 1994-05-18 | 含取代的硫杂环烯并[3,2-b]吡啶的药物组合物的制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN94105615A Expired - Lifetime CN1067076C (zh) | 1986-04-09 | 1994-05-18 | 含取代的硫杂环烯并[3,2-b]吡啶的药物组合物的制备方法 |
Country Status (20)
Country | Link |
---|---|
US (1) | US4777167A (zh) |
EP (1) | EP0241281B1 (zh) |
JP (2) | JP2613757B2 (zh) |
KR (1) | KR950014868B1 (zh) |
CN (2) | CN1028759C (zh) |
AT (1) | ATE109151T1 (zh) |
CA (1) | CA1310967C (zh) |
DE (1) | DE3750271T2 (zh) |
DK (2) | DK167021C (zh) |
ES (1) | ES2060597T3 (zh) |
FI (1) | FI93454C (zh) |
HK (1) | HK32395A (zh) |
HU (1) | HU199480B (zh) |
IE (1) | IE63854B1 (zh) |
IL (1) | IL82145A0 (zh) |
MY (1) | MY100499A (zh) |
NO (1) | NO169072C (zh) |
NZ (1) | NZ219761A (zh) |
PH (1) | PH26673A (zh) |
PT (1) | PT84648B (zh) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0308371A1 (de) * | 1987-09-18 | 1989-03-22 | Ciba-Geigy Ag | 4-Azasaccharine, 4-Aza-dihydro-oder-tetrahydrosaccharine und Verfahren zu deren Herstellung |
IT1265647B1 (it) * | 1992-11-18 | 1996-11-22 | Farmin Srl | Composizione farmaceutiche topiche per le allergie respiratorie |
DE4424678A1 (de) * | 1994-07-13 | 1996-01-18 | Bayer Ag | Dioxo-thiopyrano-pyridin-carbonsäure-derivate |
AU756505B2 (en) * | 1997-12-18 | 2003-01-16 | Abbott Laboratories | Potassium channel openers |
US6593335B1 (en) | 1997-12-18 | 2003-07-15 | Abbott Laboratories | Potassium channel openers |
US6265417B1 (en) | 1997-12-18 | 2001-07-24 | Abbott Laboratories | Potassium channel openers |
PL352760A1 (en) * | 1999-07-12 | 2003-09-08 | Ortho-Mcneil Pharmaceutical, Inc. | Oxathiepino[6,5-b |
US6472530B1 (en) * | 1999-09-22 | 2002-10-29 | Ortho-Mcneil Pharmaceutical, Inc. | Benzo-fused dithiepino[6,5-b]pyridines, and related compositions and methods |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE2616995A1 (de) * | 1976-04-17 | 1977-10-27 | Bayer Ag | 1.4-dihydropyridine mit schwefelhaltigen substituenten mehrere verfahren zu ihrer herstellung sowie ihre verwendung als arzneimittel |
US4285955A (en) * | 1978-10-31 | 1981-08-25 | Bayer Aktiengesellschaft | 1,4-Dihydropyridinecarboxylic acids |
NZ201395A (en) * | 1981-07-30 | 1987-02-20 | Bayer Ag | Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines |
JPS6210087A (ja) * | 1985-07-03 | 1987-01-19 | Shionogi & Co Ltd | 4,7−ジヒドロチエノ〔2,3−b〕ピリジン誘導体,その製造法および循環器系疾患治療剤 |
-
1987
- 1987-02-04 US US07/010,858 patent/US4777167A/en not_active Expired - Lifetime
- 1987-03-24 NZ NZ219761A patent/NZ219761A/xx unknown
- 1987-03-25 MY MYPI87000377A patent/MY100499A/en unknown
- 1987-04-07 CA CA000534050A patent/CA1310967C/en not_active Expired - Lifetime
- 1987-04-08 DK DK180487A patent/DK167021C/da active IP Right Grant
- 1987-04-08 DE DE3750271T patent/DE3750271T2/de not_active Expired - Lifetime
- 1987-04-08 KR KR1019870003323A patent/KR950014868B1/ko not_active IP Right Cessation
- 1987-04-08 EP EP87303064A patent/EP0241281B1/en not_active Expired - Lifetime
- 1987-04-08 HU HU871517A patent/HU199480B/hu unknown
- 1987-04-08 IE IE91387A patent/IE63854B1/en not_active IP Right Cessation
- 1987-04-08 AT AT87303064T patent/ATE109151T1/de not_active IP Right Cessation
- 1987-04-08 IL IL8782145A patent/IL82145A0/xx unknown
- 1987-04-08 ES ES87303064T patent/ES2060597T3/es not_active Expired - Lifetime
- 1987-04-08 FI FI871535A patent/FI93454C/fi not_active IP Right Cessation
- 1987-04-08 NO NO87871481A patent/NO169072C/no unknown
- 1987-04-09 CN CN87102761A patent/CN1028759C/zh not_active Expired - Lifetime
- 1987-04-09 PT PT84648A patent/PT84648B/pt unknown
- 1987-04-09 PH PH35117A patent/PH26673A/en unknown
-
1992
- 1992-12-08 DK DK147392A patent/DK169762B1/da active IP Right Grant
-
1994
- 1994-05-18 CN CN94105615A patent/CN1067076C/zh not_active Expired - Lifetime
-
1995
- 1995-03-09 HK HK32395A patent/HK32395A/xx not_active IP Right Cessation
- 1995-11-13 JP JP7317062A patent/JP2613757B2/ja not_active Expired - Lifetime
- 1995-11-13 JP JP7317073A patent/JP2613758B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN1426396A (zh) | 取代苯甲酸酰胺及其在抑制血管生成中的应用 | |
CN1429200A (zh) | 邻氨基苯甲酸酰胺及其作为药物的应用 | |
EP1369419B1 (en) | N-phenylarylsulfonamide compound, drug containing the compound as active ingredient, intermediate for the compound, and processes for producing the same | |
CN1040326C (zh) | 咪唑并吡啶paf/h1拮抗剂的制备方法 | |
CN87102761A (zh) | 取代硫代环链烯并(3,2-b)吡啶和其组合物的制备方法及使用方法 | |
CN1322205A (zh) | 异山梨醇一硝酸酯衍生物及其作为耐受性减少的血管扩张剂的应用 | |
CN1056880A (zh) | 新的吡啶并[2,3-f][1,4]硫代吖庚因和吡啶并[3,2-b][1,5]苯并硫代吖庚因 | |
CN1092072A (zh) | 药用组合物 | |
CN1048726C (zh) | 取代的4-苯基噻唑衍生物,其制法和含它们的药物组合物 | |
CN1227538A (zh) | 含有4-氧代-丁酸的药物组合物 | |
US4889866A (en) | Arylsulfonyl dihydropyridine derivatives | |
CN1025621C (zh) | 新型噻吩并吡喃衍生物的制备方法 | |
JP2561269B2 (ja) | 置換チアシクロアルケノ〔3,2−b〕ピリジン類 | |
CN1247593C (zh) | 噻庚英并[3,2-b]二氢吡啶和相关组合物及方法 | |
CN1069270A (zh) | 新的杂芳氧基-β-咔啉,其制备和在药品中的应用 | |
CN1055691C (zh) | 3-烷氧羰基-噻二嗪酮 | |
CN1188416C (zh) | 氧硫庚英并[6,5-b]二氢吡啶和相关组合物及其制备方法 | |
CN1370175A (zh) | 二硫杂环庚烯并(6,5-b)吡啶、和相关组合物与方法 | |
CN1176086C (zh) | 制备(5R)-甲氨基-5,6-二氢-4H-咪唑并[4,5,1-ij]喹啉-2(1H)-酮的方法 | |
CN1200720A (zh) | 新的羧酸衍生物及其制备和用途 | |
CN85107634A (zh) | 4-氧代-吡啶并(2,3-d)嘧啶-衍生物的制造方法 | |
CN85104572A (zh) | 二氢吡啶的制备方法 | |
CN1017050B (zh) | 制备1,6-二氮杂萘衍生物的方法 | |
CN1076445A (zh) | 取代的苯基喹唑啉衍生物 | |
CN1301997C (zh) | 具有钙拮抗剂活性的苯并砜 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
C15 | Extension of patent right duration from 15 to 20 years for appl. with date before 31.12.1992 and still valid on 11.12.2001 (patent law change 1993) | ||
C17 | Cessation of patent right |